• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于法国多中心CURVE研究，长春氟宁在晚期或转移性尿路上皮癌常规治疗中的疗效与安全性。

Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.

作者信息

Médioni Jacques, Di Palma Mario, Guillot Aline, Spaeth Dominique, Théodore Christine

机构信息

Medical Oncology Department, Hôpital Européen Georges Pompidou, 20, rue Leblanc, 75015, Paris, France.

Department of Medicine, Gustave Roussy Institute, 114 Rue Édouard Vaillant, 94805, Villejuif, France.

出版信息

BMC Cancer. 2016 Mar 14;16:217. doi: 10.1186/s12885-016-2262-9.

DOI:10.1186/s12885-016-2262-9
PMID:26975779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4792100/
Abstract

BACKGROUND

To retrospectively assess the efficacy and safety of Vinflunine (VFL) under routine conditions and identify overall survival (OS) prognostic factors.

METHODS

Twenty centres participated in the retrospective study (minimum 4 patients undergoing VFL treatment for advanced/metastatic UC after platinum-based regimen progression. Primary endpoint was OS. Secondary endpoints: progression-free survival (PFS), radiological response rate (RR) RECIST criteria and toxicity (CTC NCI v3).

RESULTS

These centres enrolled 134 patients. Prior chemotherapy (CT) lines (≥ 1 palliative): 1 and ≥ 2 in 69% and 26% of patients, respectively. Performance status (PS): 0, 1, 2 in 25%, 46% and 23% of patients. Median OS = 8.2 months [6.5-9.4], PFS = 4.2 months and RR 22%, median number of 5 cycles. In risk groups based on 0-3 presence of adverse prognostic factors (PS ≥ 1, haemoglobin ≤ 10 g/dl and liver metastasis), median OS: 13.2, 9.9, 3.6, and 2.4 months (P < .0001), respectively; 3.3 months (1.9-5.6) in PS ≥ 2 subgroup.

CONCLUSION

This study reflects routine UC management and confirmed VFL patient efficacy. The drug is safe with gastro-intestinal and haematological prophylaxis. Analysis of prognostic factors for OS is consistent with pivotal trials.

摘要

背景

回顾性评估长春氟宁（VFL）在常规条件下的疗效和安全性，并确定总生存期（OS）的预后因素。

方法

20个中心参与了这项回顾性研究（至少4例患者在铂类方案进展后接受VFL治疗晚期/转移性UC）。主要终点是OS。次要终点：无进展生存期（PFS）、根据实体瘤疗效评价标准（RECIST）的放射学缓解率（RR）和毒性（美国国立癌症研究所常见毒性标准第3版，CTC NCI v3）。

结果

这些中心共纳入134例患者。既往化疗（CT）线数（≥1线姑息化疗）：分别有69%和26%的患者为1线及≥2线。体能状态（PS）：0、1、2级的患者分别占25%、46%和23%。中位OS = 8.2个月[6.5 - 9.4]，PFS = 4.2个月，RR为22%，中位周期数为5个周期。在基于0 - 3个不良预后因素（PS≥1、血红蛋白≤10 g/dl和肝转移）存在情况的风险组中，中位OS分别为13.2、9.9、3.6和2.4个月（P <.0001）；PS≥2亚组为3.3个月（1.9 - 5.6）。

结论

本研究反映了常规的UC治疗情况，并证实了VFL对患者的疗效。该药物在进行胃肠道和血液学预防时是安全的。OS预后因素分析与关键试验一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5148/4792100/b73d7e0a0cba/12885_2016_2262_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5148/4792100/0c0ddad066bd/12885_2016_2262_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5148/4792100/2048c8caa8b0/12885_2016_2262_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5148/4792100/b73d7e0a0cba/12885_2016_2262_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5148/4792100/0c0ddad066bd/12885_2016_2262_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5148/4792100/2048c8caa8b0/12885_2016_2262_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5148/4792100/b73d7e0a0cba/12885_2016_2262_Fig3_HTML.jpg

相似文献

1
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.基于法国多中心CURVE研究，长春氟宁在晚期或转移性尿路上皮癌常规治疗中的疗效与安全性。
BMC Cancer. 2016 Mar 14;16:217. doi: 10.1186/s12885-016-2262-9.
2
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).意大利多中心研究（MOVIE-GOIRC 01-2014）：复发铂类治疗转移性尿路上皮癌患者用长春氟宁的真实临床实践结果。
BMC Cancer. 2017 Jul 19;17(1):493. doi: 10.1186/s12885-017-3466-3.
3
Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.长春氟宁在晚期或转移性尿路上皮癌常规临床治疗中的应用——来自一项前瞻性多中心研究的数据
BMC Cancer. 2015 Jun 4;15:455. doi: 10.1186/s12885-015-1434-3.
4
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.在接受含铂方案治疗后的晚期尿路上皮移行细胞癌患者中，长春氟宁联合最佳支持治疗与单纯最佳支持治疗的III期试验。
J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534. Epub 2009 Aug 17.
5
Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.长春氟宁在铂类化疗难治的晚期尿路上皮癌患者中的安全性：一项前瞻性试点研究。
Curr Drug Saf. 2019;14(1):31-36. doi: 10.2174/1574886313666181001120752.
6
The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.斯洛伐克首次使用二线长春氟宁治疗晚期尿路上皮癌的经验。
Klin Onkol. 2014;27(6):429-33. doi: 10.14735/amko2014429.
7
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.在一线化疗后有缓解的晚期尿路上皮癌患者中，使用长春氟宁联合最佳支持治疗与最佳支持治疗相比的维持治疗（MAJA；SOGUG 2011/02）：一项多中心、随机、对照、开放标签、二期临床试验。
Lancet Oncol. 2017 May;18(5):672-681a. doi: 10.1016/S1470-2045(17)30242-5. Epub 2017 Apr 4.
8
Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data.含铂方案治疗失败后，晚期或转移性尿路上皮癌患者接受静脉注射长春氟宁单药治疗：德国常规数据的回顾性分析
Urol Int. 2014;92(2):174-9. doi: 10.1159/000354751. Epub 2013 Dec 11.
9
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.阿维鲁单抗治疗铂类治疗失败后的转移性尿路上皮癌（JAVELIN Solid Tumor）：一项开放标签、1 期试验两个扩展队列的汇总结果。
Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5.
10
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.优化大小变异阈值，以评估接受长春氟宁治疗的铂类耐药性晚期尿路上皮移行细胞癌患者的影像学反应。
Eur J Cancer. 2012 Jul;48(10):1495-502. doi: 10.1016/j.ejca.2011.11.018. Epub 2011 Dec 14.

引用本文的文献

1
Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data.局部晚期或转移性尿路上皮细胞癌的化疗：单中心真实世界数据
Cancer Manag Res. 2020 Jun 26;12:5077-5084. doi: 10.2147/CMAR.S231508. eCollection 2020.
2
A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.一项评估德国局部晚期和转移性尿路上皮癌患者一线和二线治疗的治疗模式、临床特征及生存结局的真实世界数据研究。
J Cancer. 2018 Mar 29;9(8):1337-1348. doi: 10.7150/jca.23162. eCollection 2018.
3

本文引用的文献

1
Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.长春氟宁在晚期或转移性尿路上皮癌常规临床治疗中的应用——来自一项前瞻性多中心研究的数据
BMC Cancer. 2015 Jun 4;15:455. doi: 10.1186/s12885-015-1434-3.
2
Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.在临床实践中，对于一线铂类全身治疗失败后的转移性尿路上皮移行细胞癌患者，长春氟宁的安全性和有效性。
BMC Cancer. 2014 Oct 24;14:779. doi: 10.1186/1471-2407-14-779.
3
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy.
长春氟宁用于治疗晚期或转移性尿路上皮移行细胞癌：基于证据的安全性、有效性及治疗地位综述
Core Evid. 2018 Jan 24;13:1-12. doi: 10.2147/CE.S118670. eCollection 2018.
4
Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.更好地描述长春氟宁的药代动力学变异性和暴露/毒性关系，以改善其应用：来自 18 项试验的分析。
Br J Clin Pharmacol. 2018 May;84(5):900-910. doi: 10.1111/bcp.13518. Epub 2018 Feb 26.
5
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).意大利多中心研究（MOVIE-GOIRC 01-2014）：复发铂类治疗转移性尿路上皮癌患者用长春氟宁的真实临床实践结果。
BMC Cancer. 2017 Jul 19;17(1):493. doi: 10.1186/s12885-017-3466-3.
6
Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.长春氟宁治疗晚期尿路上皮癌：临床证据与经验
Ther Adv Urol. 2017 Jan;9(1):28-35. doi: 10.1177/1756287216677903. Epub 2016 Nov 21.
7
Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).转移性膀胱癌：加利西亚肿瘤学会泌尿生殖肿瘤分会（SOG-GU）的二线治疗及建议
Curr Oncol Rep. 2016 Dec;18(12):72. doi: 10.1007/s11912-016-0556-3.
8
Role of surgical consolidation in metastatic urothelial carcinoma.手术巩固在转移性尿路上皮癌中的作用。
Curr Opin Urol. 2016 Nov;26(6):573-80. doi: 10.1097/MOU.0000000000000329.
[CCAFU Recommendations 2013: Diagnosis, treatment, follow up of urological cancers].
[《中国抗癌协会泌尿男生殖系肿瘤指南2013：泌尿系统肿瘤的诊断、治疗及随访》]
Prog Urol. 2013 Nov;23 Suppl 2:S51-4. doi: 10.1016/S1166-7087(13)70046-0.
4
[CCAFU Recommendations 2013: Bladder carcinoma].[中国抗癌协会泌尿男生殖系肿瘤专业委员会2013年膀胱癌诊疗指南]
Prog Urol. 2013 Nov;23 Suppl 2:S105-25. doi: 10.1016/S1166-7087(13)70049-6.
5
New treatments for bladder cancer: when will we make progress?膀胱癌的新疗法：我们何时才能取得进展？
Curr Treat Options Oncol. 2014 Mar;15(1):99-114. doi: 10.1007/s11864-013-0271-3.
6
New therapeutic targets in the management of urothelial carcinoma of the bladder.膀胱尿路上皮癌治疗中的新治疗靶点
Res Rep Urol. 2013 Mar 1;5:53-65. doi: 10.2147/RRU.S29131.
7
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.EAU 指南：肌层浸润性和转移性膀胱癌：2013 年指南摘要。
Eur Urol. 2014 Apr;65(4):778-92. doi: 10.1016/j.eururo.2013.11.046. Epub 2013 Dec 12.
8
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.在铂类化疗失败的晚期尿路上皮癌患者中，长春氟宁联合最佳支持治疗与单纯最佳支持治疗的随机 III 期试验的长期生存结果。
Ann Oncol. 2013 Jun;24(6):1466-72. doi: 10.1093/annonc/mdt007. Epub 2013 Feb 17.
9
Urothelial carcinoma of the bladder: definition, treatment and future efforts.膀胱尿路上皮癌：定义、治疗和未来努力。
Nat Rev Urol. 2011 Oct 11;8(11):631-42. doi: 10.1038/nrurol.2011.144.
10
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.膀胱癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2011 Sep;22 Suppl 6:vi45-9. doi: 10.1093/annonc/mdr376.